Academy Capital Management Inc. TX decreased its stake in Core Laboratories (NYSE:CLB) by 1.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 66,733 shares of the oil and gas company’s stock after selling 846 shares during the period. Core Laboratories accounts for about 1.9% of Academy Capital Management Inc. TX’s holdings, making the stock its 21st biggest holding. Academy Capital Management Inc. TX owned 0.15% of Core Laboratories worth $6,586,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Callahan Advisors LLC grew its stake in Core Laboratories by 2.5% during the second quarter. Callahan Advisors LLC now owns 2,075 shares of the oil and gas company’s stock worth $210,000 after purchasing an additional 50 shares during the period. Janus Henderson Group PLC grew its stake in Core Laboratories by 1.3% during the second quarter. Janus Henderson Group PLC now owns 5,002 shares of the oil and gas company’s stock worth $506,000 after purchasing an additional 64 shares during the period. Laurel Wealth Advisors Inc. grew its stake in Core Laboratories by 3.2% during the first quarter. Laurel Wealth Advisors Inc. now owns 2,071 shares of the oil and gas company’s stock worth $239,000 after purchasing an additional 65 shares during the period. First Bank & Trust grew its stake in Core Laboratories by 5.8% during the second quarter. First Bank & Trust now owns 1,493 shares of the oil and gas company’s stock worth $152,000 after purchasing an additional 82 shares during the period. Finally, ProShare Advisors LLC grew its stake in Core Laboratories by 2.3% during the second quarter. ProShare Advisors LLC now owns 3,889 shares of the oil and gas company’s stock worth $394,000 after purchasing an additional 87 shares during the period.

WARNING: “Academy Capital Management Inc. TX Sells 846 Shares of Core Laboratories (CLB)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/23/academy-capital-management-inc-tx-sells-846-shares-of-core-laboratories-clb.html.

CLB has been the subject of several recent analyst reports. Deutsche Bank AG initiated coverage on Core Laboratories in a research note on Tuesday, October 10th. They set a “buy” rating and a $109.00 target price for the company. Zacks Investment Research lowered Core Laboratories from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. ValuEngine lowered Core Laboratories from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Royal Bank Of Canada cut their price target on Core Laboratories from $115.00 to $112.00 and set an “outperform” rating on the stock in a report on Thursday, September 7th. Finally, Credit Suisse Group upgraded Core Laboratories from a “neutral” rating to an “outperform” rating and set a $110.00 price target on the stock in a report on Thursday, August 24th. They noted that the move was a valuation call. Four analysts have rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the stock. Core Laboratories currently has an average rating of “Hold” and an average price target of $110.91.

Core Laboratories (CLB) traded down 0.8382% during mid-day trading on Monday, reaching $88.7399. The company’s stock had a trading volume of 87,937 shares. The company has a 50-day moving average price of $94.95 and a 200-day moving average price of $101.45. The firm has a market cap of $3.92 billion, a PE ratio of 54.4417 and a beta of 1.64. Core Laboratories has a 12-month low of $86.55 and a 12-month high of $125.83.

Core Laboratories (NYSE:CLB) last released its quarterly earnings results on Monday, July 24th. The oil and gas company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.01. The firm had revenue of $163.90 million for the quarter, compared to analysts’ expectations of $168.23 million. Core Laboratories had a return on equity of 61.31% and a net margin of 13.86%. The company’s revenue was up 10.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.35 EPS. On average, equities research analysts expect that Core Laboratories will post $1.96 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 21st. Stockholders of record on Friday, October 20th will be paid a $0.55 dividend. The ex-dividend date is Thursday, October 19th. This represents a $2.20 annualized dividend and a dividend yield of 2.46%. Core Laboratories’s dividend payout ratio (DPR) is 134.15%.

Core Laboratories Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Stock Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related stocks with our FREE daily email newsletter.